GlassScriptPhysician profile
Tamara Brigitte Patterson
NPI 1164663605
$10,690.62
in general payments reported to CMS, 2019-2025
31 companies · $2,819 in 2025
The $2,819 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $979 · 2022: $1,376 · 2023: $2,375 · 2024: $3,141 · 2025: $2,819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,141 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,141.42 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,548.12 | 2021-2025 | |
| Pfizer INC. | $1,259.47 | 2021-2025 | |
| Incyte Corporation | $1,007.71 | 2022-2025 | Opzelura, Opzelura |
| Janssen Biotech, INC. | $997.57 | 2021-2025 | Tremfya, Simponi, Stelara |
| E.R. Squibb & Sons, L.L.C. | $784.66 | 2022-2025 | Sotyktu |
| Amgen INC. | $538.65 | 2021-2025 | Otezla, Otezla, Enbrel |
| Dermavant Sciences, INC. | $525.38 | 2022-2024 | Vtama |
| Leo Pharma INC. | $508.89 | 2021-2025 | Adbry, Anzupgo |
| Medimetriks Pharmaceuticals, INC. | $462.07 | 2022-2025 | Neo-Synalar, Ketodan |
| Lilly USA, LLC | $428.94 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $384.43 | 2022-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $325.09 | 2022-2025 | |
| Galderma Laboratories, L.P. | $263.66 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Novartis Pharmaceuticals Corporation | $219.31 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $210.46 | 2021-2025 | Winlevi, Absorica Ld |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $209.41 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $189.63 | 2023-2025 | Dupixent |
| Botanix Sb INC | $119.42 | 2025 | Sofdra |
| Organon LLC | $118.37 | 2024-2025 | Vtama |
| Journey Medical Corporation | $106.75 | 2023-2024 | |
| Arcutis Biotherapeutics, INC. | $101.43 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $99.12 | 2021-2024 | Jublia, Cabtreo, Arazlo |
| Almirall LLC | $60.60 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $41.91 | 2021 | |
| Epi Health, LLC | $38.99 | 2022 | |
| Sebela Pharmaceuticals INC. | $33.14 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.99 | 2023 | Spevigo |
| Kyowa Kirin, INC. | $26.80 | 2022 | |
| Revance Therapeutics, INC. | $24.81 | 2024 | Daxxify |
| Dermira, INC. | $17.54 | 2021 | |
| Biofrontera INC. | $10.30 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.